MALVERN, PA — YPrime has been named a Leader in the Everest Group’s 2025 Life Sciences Electronic Clinical Outcome Assessment (eCOA) Products PEAK Matrix® Assessment, a recognition that underscores the company’s ability to support large-scale, complex clinical trials with advanced technology and operational excellence.
The PEAK Matrix® evaluates providers on vision, capability, and market impact. YPrime’s placement in the Leader quadrant reflects its role as a trusted partner to pharmaceutical companies, biotechs, and contract research organizations (CROs) seeking faster and more reliable study launches.
“We’re proud to be named a Leader by Everest Group,” said Mike Hughes, Chief Product Officer at YPrime. “Our eCOA platform is built to meet the complexity and speed that today’s clinical trials demand—while simplifying processes and improving the experience for patients, sites, and sponsors alike.”
YPrime has introduced several innovations designed to streamline global trial operations. Its AI-powered localization tools automate and validate translation processes, enabling sponsors to deploy studies in more than 250 languages across 100 countries. This approach reduces delays and ensures linguistic accuracy, addressing a longstanding challenge in multinational trials.
Another advancement, the Automated Data Change Form (DCF), allows site staff to execute protocol-compliant data edits in minutes rather than days. The feature simplifies approvals while maintaining full audit trails, improving both efficiency and data integrity.
YPrime has also invested in device integration, notably with a glucometer feature developed in collaboration with diabetes patients. This integration supports metabolic and autoimmune trials by pairing devices seamlessly, categorizing glucose readings, and sending real-time alerts to improve adherence and compliance. The capability is already being used in GLP-1 and other metabolic studies by major global sponsors.
“Being named a Leader highlights the strength of our platform and the quality of service we deliver to clinical trial sponsors and CROs every day,” said YPrime President Mark Maietta. “It reinforces our commitment to innovation, global scalability, and the operational excellence patients and sites rely on to run better trials.”
YPrime’s recognition builds on its previous designation as a Trailblazer in Patient Engagement by Everest Group in 2024, further solidifying its position as a leader in digital tools designed to reduce trial friction and improve participation.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.